The impact of psilocybin and eugenol on brain inflammation in murine models: unraveling cumulative and individual effects

Simple item page
dc.contributor.authorZanikov, Timur
dc.contributor.authorUniversity of Lethbridge. Faculty of Arts and Science
dc.contributor.supervisorKovalchuk, Igor
dc.contributor.supervisorKovalchuk, Olga
dc.date.accessioned2024-03-25T16:50:10Z
dc.date.available2024-03-25T16:50:10Z
dc.date.issued2023
dc.degree.levelMasters
dc.description.abstractNeuroinflammation represents a unique immune response within the central nervous system, involving glial cells such as microglia and astrocytes. Unlike peripheral inflammation, neuroinflammation affects the blood-brain barrier, glia, and neurons. Various factors can induce neuroinflammation, including surgical procedures, infections, traumatic brain injuries, toxin exposure, and immune dysregulation, involving interactions between multiple cell types and signaling molecules. Neuroinflammation is a critical factor in various acute and chronic brain diseases. Recent research has emphasized the potential anti-inflammatory properties of naturally occurring compounds from mushrooms and plants. This study aimed to investigate the effects of psilocybin and eugenol, individually and in combination, on neuroinflammation. We used two different models to study the effects of treatment on neuroinflammation. First, we used lipopolysaccharide (LPS) model to examine if our treatments can prevent an increase in cytokine levels in the brains of mice injected with LPS. Second, we utilized dextran sulfate sodium (DSS) model to assess the combined anti-inflammatory effects of psilocybin and eugenol. While both psilocybin and eugenol individually displayed anti-inflammatory effects, their combined treatment demonstrated an additive effect on the reduction in neuroinflammation. This study adds to the growing body of evidence supporting the therapeutic potential of psilocybin and eugenol in psychiatric and neurodegenerative inflammatory disorders, with further research needed to understand their underlying mechanisms and clinical efficacy.
dc.embargoNo
dc.identifier.urihttps://hdl.handle.net/10133/6729
dc.language.isoen
dc.proquest.subject0306
dc.proquest.subject0307
dc.proquest.subject0317
dc.proquestyesYes
dc.publisherLethbridge, Alta. : University of Lethbridge, Dept. of Biological Sciences
dc.publisher.departmentDepartment of Biological Sciences
dc.publisher.facultyArts and Science
dc.relation.ispartofseriesThesis (University of Lethbridge. Faculty of Arts & Science)
dc.subjectneuroinflammation
dc.subjectbrain inflammation
dc.subjectpsilocybin
dc.subjecteugenol
dc.subjectanti-inflammatories
dc.subjectlipopolysaccharide model
dc.subjectdextran sulfate sodium model
dc.subject.lcshCentral nervous system
dc.subject.lcshInflammation--Research
dc.subject.lcshInflammation--Animal models
dc.subject.lcshEncephalitis--Molecular aspects
dc.subject.lcshPsilocybin--Research
dc.subject.lcshPsilocybin--Therapeutic use--Research
dc.subject.lcshEugenol--Research
dc.subject.lcshEugenol--Therapeutic use--Research
dc.subject.lcshAnti-inflammatory agents--Research
dc.subject.lcshMice as laboratory animals
dc.subject.lcshDissertations, Academic
dc.titleThe impact of psilocybin and eugenol on brain inflammation in murine models: unraveling cumulative and individual effects
dc.typeThesis
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ZANIKOV_TIMUR_MSC_2023.pdf
Size:
3.62 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
3.25 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Arts and Science, Faculty of
University of Lethbridge Theses